Apr 30 |
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
|
Apr 22 |
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
|
Apr 17 |
FSD Pharma expands pipeline investigation to include weight loss and liver health products
|
Apr 17 |
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
|
Apr 15 |
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
|
Apr 8 |
FSD Pharma receives Nasdaq notification regarding minimum bid price deficiency
|
Apr 8 |
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
|
Apr 2 |
FSD Pharma GAAP EPS of -$0.46
|
Mar 30 |
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
|
Mar 27 |
FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
|